Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy.

Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6474-9.

2.
3.

Products of advanced glycation in patients with type 2 diabetes and vascular disease.

Turk Z, Sesto M, Skodlar J, Ferencak G, Pokupec R, Turk N, Stavljenić-Rukavina A.

Ann Clin Biochem. 2003 Sep;40(Pt 5):552-9.

PMID:
14503994
5.

[Tuberculosis in compromised hosts].

[No authors listed]

Kekkaku. 2003 Nov;78(11):717-22. Japanese.

PMID:
14672050
6.

Increased serum levels of advanced glycation end-products and diabetic complications.

Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y.

Diabetes Res Clin Pract. 1998 Aug;41(2):131-7.

PMID:
9789719
7.

Advanced glycation end products in adolescents and young adults with diabetic angiopathy.

Chiarelli F, Catino M, Tumini S, Cipollone F, Mezzetti A, Vanelli M, Verrotti A.

Pediatr Nephrol. 2000 Aug;14(8-9):841-6.

PMID:
10955941
8.

Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.

Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, Sharma SK, Cross MR, Dutt C.

Clin Drug Investig. 2009;29(9):559-75. doi: 10.2165/11315260-000000000-00000.

PMID:
19663519
10.

Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure.

Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, Rossini B, Cecilia A, Di Franco D, Straccialano E, Casciani CU.

J Ren Nutr. 2004 Oct;14(4):208-13.

PMID:
15483780
11.

Advanced glycation end products and endothelial dysfunction in type 2 diabetes.

Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS.

Diabetes Care. 2002 Jun;25(6):1055-9.

PMID:
12032114
12.

Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.

Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Schmidt AM, Fiehn W, Ziegler R, Wahl P, Nawroth PP.

Diabetes Care. 1998 May;21(5):841-8.

PMID:
9589252
13.

Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy.

Piwowar A, Knapik-Kordecka M, Szczecińska J, Warwas M.

Diabetes Metab Res Rev. 2008 Oct;24(7):549-53. doi: 10.1002/dmrr.885.

PMID:
18613218
14.

Urinary albumin excretion is correlated to fibrinogen levels and protein S activity in patients with type 1 diabetes mellitus without overt diabetic nephropathy.

Lengyel Z, Vörös P, Tóth LK, Németh C, Kammerer L, Mihály M, Tornóci L, Rosivall L.

Wien Klin Wochenschr. 2004 Apr 30;116(7-8):240-5.

PMID:
15143863
15.
16.

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.

Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB.

Am J Nephrol. 2007;27(6):605-14. Epub 2007 Sep 6.

PMID:
17823506
17.
18.
19.

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.

Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.

Microvasc Res. 2008 May;76(1):52-6. doi: 10.1016/j.mvr.2007.09.004. Epub 2007 Oct 5.

PMID:
18474381
20.

Advanced glycosylation end products in patients with diabetic nephropathy.

Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H.

N Engl J Med. 1991 Sep 19;325(12):836-42.

Supplemental Content

Support Center